Investor Relations

Recent Event

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Latest Financial Results

Q2 2020

Quarter Ended Jun 30, 2020

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

Company Overview

CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors.

Our lead drug, Berubicin, is an exciting discovery for the treatment of Glioblastoma Multiforme (GBM) and potentially for other CNS malignancies. Berubicin was first discovered at the largest cancer institutes in the world.

CNS has obtained a worldwide exclusive license to the Berubicin patent from Houston Pharmaceuticals, the original commercial holder of the Berubicin intellectual property.

CNS has also acquired all data and know-how related to the Phase 1 trial of Berubicin from Reata Pharmaceuticals, a multibillion dollar NASDAQ listed company. In 2017, CNS entered into a collaboration agreement with Reata to further advance the development of Berubicin.

In 2020, with the funding secured from our NASDAQ IPO, CNS will commence its Phase 2(a) clinical trial of Berubicin for the treatment of GBM.

CNS may also pursue the development of Berubicin to treat additional diseases, including pancreatic and ovarian cancers and lymphoma. CNS may also develop combination therapies that include Berubicin.

Investor Contact Information


CNS Pharmaceuticals, Inc.
2100 West Loop South
Suite 900
Houston, TX 77027

Investor Relations

[email protected]

Transfer Agent

Continental Stock Transfer & Trust Company
1 State Street
30th Floor
New York, NY 10004
T: 800-509-5586
[email protected]